Use of imidazopyrimidine or imidazotriazine compounds for the prevention, alleviation or treatment of developmental disorders
Imidazopyrimidine and imidazotriazine compounds provide therapeutic benefits for developmental disorders by targeting genetic mutations, reducing symptoms like fear conditioning and hyperactivity in mouse models.
Patent Information
- Application Number
- JP2022523479
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-21
- Filing Date
- 2020-10-21
- Publication Date
- 2025-11-06
- Estimated Expiration
- 2040-10-21
AI Technical Summary
Current treatments for developmental disorders such as Fragile X Syndrome, Angelman Syndrome, and Rett Syndrome are limited, and there is a need for effective therapeutic agents to address symptoms like developmental delay, learning disabilities, intellectual disability, social behavioral disorders, and seizures.
Development of imidazopyrimidine and imidazotriazine compounds represented by formula (1) or their pharmaceutically acceptable salts, solvates, or hydrates, which are administered to alleviate or treat developmental disorders by targeting underlying genetic mutations.
The compounds effectively reduce symptoms of developmental disorders, including fear conditioning, anxiety, and hyperactivity, as demonstrated in Fmr1 gene knockout mouse models.